Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1977
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use ; volume:35 ; number:1 ; day:27 ; month:12 ; year:2018 ; pages:50 ; date:1.2019
Drugs & therapy perspectives ; 35, Heft 1 (27.12.2018), 50, 1.2019
- Creator
-
Scott, Lesley J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40267-018-0594-z
- URN
-
urn:nbn:de:101:1-2019021201513005559319
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Scott, Lesley J.
- SpringerLink (Online service)
Other Objects (12)
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Effect of the First-Line Therapy with Osimertinib for a Metastatic Choroidal Tumor in Advanced-Stage Lung Cancer: A Case Report
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Effect of the First-Line Therapy with Osimertinib for a Metastatic Choroidal Tumor in Advanced-Stage Lung Cancer: A Case Report
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Effect of the First-Line Therapy with Osimertinib for a Metastatic Choroidal Tumor in Advanced-Stage Lung Cancer: A Case Report
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study